{
  "title": "146 Bret Jensen - Upcoming Catalysts For Biotech (PLUS: 2 Small Cap Picks)",
  "pubDate": "Wed, 29 Mar 2017 00:57:36 +0000",
  "guid": "4047d2625ede3d72d93088517c98e0ae",
  "link": "https://investorinthefamily.libsyn.com/146-bret-jensen-upcoming-catalysts-for-biotech-plus-2-small-cap-picks",
  "itunes:image": "",
  "description": "<p>Biotech update from Bret Jensen.</p> <p><a href= \"http://investorinthefamily.com/\">http://investorinthefamily.com/</a> </p> <ul> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Outperforming market in 2017 after 18 month bear</span></li> <li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Big uptick in M&A in Jan</span></li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">3 big deals</span></li> </ul> </li> <li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Feb and Mar have been fairly flat</span></li> <li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Lots of resistance technically</span></li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Need an uptick in MA or earnings to break through</span></li> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Expect the uptick to happen in MA</span></li> </ul> </li> <li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Watch Trump’s actions and not words</span></li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Has appointed 2 free market minded people (FDA,</span></li> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Proposed to double fees for drug approval</span></li> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Watching repeal and replace of ACA</span></li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Needs to happen before tax and regulatory reform</span></li> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Expect the repeal to happen by April or May</span></li> </ul> </li> </ul> </li> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Ocular Therapeutix (OCUL)</span></li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Trigger event in July, new product for cataract surgery</span></li> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Insider buying</span></li> </ul> </li> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Omerisk (OMER)</span></li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">OMS721</span></li> <li style=\"font-weight: 400;\"><span style= \"font-weight: 400;\">Priced at just over $10 w PTs in the $30</span></li> <li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Next trigger event in few years</span></li> </ul> </li> </ul>",
  "content:encoded": "<p>Biotech update from Bret Jensen.</p> <p><a href= \"http://investorinthefamily.com/\">http://investorinthefamily.com/</a> </p> <ul> <li style=\"font-weight: 400;\">Outperforming market in 2017 after 18 month bear</li> <li style=\"font-weight: 400;\">Big uptick in M&A in Jan</li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\">3 big deals</li> </ul> </li> <li style=\"font-weight: 400;\">Feb and Mar have been fairly flat</li> <li style=\"font-weight: 400;\">Lots of resistance technically</li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\">Need an uptick in MA or earnings to break through</li> <li style=\"font-weight: 400;\">Expect the uptick to happen in MA</li> </ul> </li> <li style=\"font-weight: 400;\">Watch Trump’s actions and not words</li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\">Has appointed 2 free market minded people (FDA,</li> <li style=\"font-weight: 400;\">Proposed to double fees for drug approval</li> <li style=\"font-weight: 400;\">Watching repeal and replace of ACA</li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\">Needs to happen before tax and regulatory reform</li> <li style=\"font-weight: 400;\">Expect the repeal to happen by April or May</li> </ul> </li> </ul> </li> <li style=\"font-weight: 400;\">Ocular Therapeutix (OCUL)</li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\">Trigger event in July, new product for cataract surgery</li> <li style=\"font-weight: 400;\">Insider buying</li> </ul> </li> <li style=\"font-weight: 400;\">Omerisk (OMER)</li> <li style=\"list-style: none; display: inline\"> <ul> <li style=\"font-weight: 400;\">OMS721</li> <li style=\"font-weight: 400;\">Priced at just over $10 w PTs in the $30</li> <li style=\"font-weight: 400;\">Next trigger event in few years</li> </ul> </li> </ul>",
  "enclosure": "",
  "itunes:duration": "14:48",
  "itunes:explicit": false,
  "itunes:keywords": "",
  "itunes:subtitle": "Biotech update from Bret Jensen.    Outperforming market in 2017 after 18 month bear Big uptick in M&A in Jan   3 big deals   Feb and Mar have been fairly flat Lots of resistance technically   Need an uptick in MA or earnings to break through..."
}